The healthcare IT company will fund early-stage companies developing disruptive healthcare technology.

Wuxi Pharmatech invested alongside Fidelity Worldwide Investments as Adagene closed its series A round.

The entertainment producer will put up 20% of the capital for the fund, which will invest in a diverse range of sectors.

Intrexon-backed regenerative medicine company Histogenics went public after raising $89m in venture capital.

The medical device maker raised the money in an Edwards Lifesciences-led round as part of an agreement that could involve Edwards acquiring the company.

Pharmstandard has participated in a series B round for the biopharmaceutical company, which focuses on metabolic and orphan diseases.

Queensland life sciences spin-out Protagonist Therapeutics closes second tranche of $18m series B round.